Skip to main content
Caplight Logo









ImmunoShield Therapeutics

ImmunoShield Therapeutics

Private
Phoenix, ArizonaHealthcare & Life Scienceshttps://immunoshieldtherapeutics.com/

Last Round

Grant

Jun 9, 2025

Total Funding Raised

$298,364

Company Overview

ImmunoShield Therapeutics is a biotechnology company that develops cell encapsulation and immune tolerance technologies designed to reduce rejection and expand patient access to allogeneic cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

cell encapsulationallogeneic cell therapyimmune tolerancehydrogel devicebio-implantregenerative medicineType 1 Diabetesbiomaterialsimmuno-evasioncell therapy platformbiomanufacturingcell deliverySBIRsmall business innovation research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoShield Therapeutics Comparables

Compare ImmunoShield Therapeutics with similar companies based on industry and business-model similarity.

ImmunoShield Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Procyon Technologies LLC
91%
Encellin
83%
ALTuCELL
81%

ImmunoShield Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 9, 2025
GrantMay 30, 2023

Key People

Founding team and executive leadership

Matthew Becker

Chief Executive Officer

Executive Team

ImmunoShield Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 9, 2025

    Received $1.88M from the National Institute of Diabetes and Digestive and Kidney Diseases.

  • May 30, 2023

    Received funding from the Flinn Foundation.

ImmunoShield Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmunoShield Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunoShield Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhoenix, Arizona
Employee Range3
Year Founded2022
Last FundingJun 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?